Reuters logo
BRIEF-J&J says Pimodivir alone or in combination with oseltamivir demonstrated a significant reduction in viral load in adults with Influenza A
June 14, 2017 / 11:23 AM / 6 months ago

BRIEF-J&J says Pimodivir alone or in combination with oseltamivir demonstrated a significant reduction in viral load in adults with Influenza A

June 14 (Reuters) - Johnson & Johnson

* Pimodivir alone or in combination with oseltamivir demonstrated a significant reduction in viral load in adults with Influenza A

* No significant safety concerns were noted with pimodivir treatment in study

* Pimodivir, discovered by vertex pharmaceuticals, is a inhibitor of PB2 subunit of Influenza A polymerase complex

* Phase 3 studies for treatment with pimodivir are anticipated to start in second half of 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below